| |
| Names | |
|---|---|
|
Preferred IUPAC name
7-Chloro-4-oxo-1,4-dihydroquinoline-2-carboxylic acid | |
| Other names
7-chlorokynurenate; 7-CTKA
| |
| Identifiers | |
|
3D model (JSmol)
|
|
| ChemSpider | |
| ECHA InfoCard | 100.038.088 |
|
PubChem CID
|
|
| UNII | |
|
CompTox Dashboard (EPA)
|
|
| |
| Properties | |
| C10H6Cl1N1O3 | |
| Molar mass | 223.61254 g/mol |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
7-Chlorokynurenic acid (7-CKA) is a tool compound that acts as a potent and selective competitive antagonist of the glycine site of the NMDA receptor. It produces ketamine-like rapid antidepressant effects in animal models of depression. However, 7-CKA is unable to cross the blood-brain-barrier, and for this reason, is unsuitable for clinical use. As a result, a centrally-penetrant prodrug of 7-CKA, 4-chlorokynurenine (AV-101), has been developed for use in humans, and is being studied in clinical trials as a potential treatment for major depressive disorder, and anti-nociception. In addition to antagonizing the NMDA receptor, 7-CKA also acts as a potent inhibitor of the reuptake of glutamate into synaptic vesicles (or as a vesicular glutamate reuptake inhibitor), an action that it mediates via competitive blockade of vesicular glutamate transporters (Ki = 0.59 mM).